Clinical trial
Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or…
NCT00240422 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00240422 |
|---|---|
| Title | Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes |
| Official title | A Prospective, Randomized, Double-blind, Double-dummy, Forced Titration, Parallel Group Comparison, Multicenter Trial to Compare the Effects of Either Telmisartan (40-80 mg p.o. Once Daily) or Ramipril (5-10 mg p.o. Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2, Hypertension |
| Intervention type | Drug |
| Interventions | Telmisartan, Ramipril |
| Enrollment | 96 |
| Start date | Feb 1, 2003 |
| Completion | Jul 1, 2004 |
| First posted | Oct 18, 2005 |
| Last update posted | Nov 8, 2013 |
| Countries | France, Germany, Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: